QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
State of |
||
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) | |
(Address of Principal Executive Offices) |
(Zip Code) |
Title of each class |
Trading Symbol (s) |
Name of each exchange on which registered | ||
one-half of one Warrant |
||||
Large Accelerated Filer | ☐ | Accelerated Filer | ☐ | |||
Non-Accelerated Filer |
☒ | Smaller Reporting Company | ||||
Emerging Growth Company |
Page |
||||||
2 |
||||||
PART I-FINANCIAL INFORMATION |
||||||
Item 1. |
4 |
|||||
4 |
||||||
5 |
||||||
6 |
||||||
7 |
||||||
8 |
||||||
Item 2. |
19 |
|||||
Item 3. |
22 |
|||||
Item 4. |
23 |
|||||
PART II-OTHER INFORMATION |
||||||
Item 1. |
23 |
|||||
Item 1A. |
23 |
|||||
Item 2. |
24 |
|||||
Item 3. |
24 |
|||||
Item 4. |
24 |
|||||
Item 5. |
24 |
|||||
Item 6. |
24 |
|||||
26 |
• |
Our independent registered public accounting firm’s report contains an explanatory paragraph that expresses substantial doubt about our ability to continue as a “going concern.” |
• |
We may not be able to complete our initial business combination within 18 months after the closing of our initial public offering, in which case we would cease all operations except for the purpose of winding up, and we would redeem our Public Shares (as defined herein) for a pro rata portion of the funds in the trust account, and we would liquidate. In such event, our warrants would expire worthless. |
• |
Your only opportunity to affect the investment decision regarding a potential business combination will be limited to the exercise of your right to redeem your shares from us for cash, unless we seek stockholder approval of such business combination. |
• |
Our initial stockholders will control a substantial interest in us and thus may influence certain actions requiring a stockholder vote. |
• |
We may not obtain a fairness opinion with respect to the target business that we seek to acquire and therefore you may be relying solely on the judgment of our board of directors in approving a proposed business combination. |
• |
Our outstanding warrants may have an adverse effect on the market price of our common stock and make it more difficult to effectuate our initial business combination. |
• |
We may issue additional shares of capital stock or debt securities to complete a business combination, which would reduce the equity interest of our stockholders and likely cause a change in control of our ownership. |
• |
We may be unable to obtain additional financing, if required, to complete a business combination or to fund the operations and growth of the target business. |
• |
Resources could be wasted in researching acquisitions that are not consummated, which could materially adversely affect subsequent attempts to locate and acquire or merge with another business. |
• |
Our search for a business combination, and any target business with which we ultimately consummate a business combination, may be materially adversely affected by the recent coronavirus (COVID-19) pandemic and other events, and the status of debt and equity markets. |
• |
We may have a limited ability to assess the management of a prospective target business and, as a result, may consummate our initial business combination with a target business whose management may not have the skills, qualifications or abilities to manage a public company. |
• |
There may be tax consequences to our initial business combination that may adversely affect us. |
• |
Our officers and directors presently have fiduciary or contractual obligations to other entities and, accordingly, may have conflicts of interest in determining to which entity a particular business opportunity should be presented. |
• |
Our officers and directors may have interests in a potential business combination that are different than yours, which may create conflicts of interest. |
• |
Nasdaq may delist our securities from trading on its exchange, which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions. |
• |
We may amend the terms of the warrants in a manner that may be adverse to holders of public warrants with the approval by the holders of at least a majority of the then outstanding public warrants. |
• |
We may amend the terms of our warrant agreement to allow for our warrants to be classified as equity in our financial statements with the approval by the holders of at least a majority of the public warrants and the private placement warrants, voting together as a single class. |
• |
We may redeem your unexpired warrants prior to their exercise at a time that is disadvantageous to you, thereby making your warrants effectively worthless. |
• |
If third parties bring claims against us, and if our directors decide not to enforce the indemnification obligations of our sponsor, or if our sponsor does not have the funds to indemnify us, the proceeds held in the trust account could be reduced and the per share redemption amount received by stockholders may be less than $10.00 per share. |
• |
Provisions in our amended and restated certificate of incorporation and bylaws and Delaware law may inhibit a takeover of us, which could limit the price investors might be willing to pay in the future for our common stock and could entrench management. |
• |
Our amended and restated certificate of incorporation provides, subject to limited exceptions, that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for certain stockholder litigation matters, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or stockholders. |
• |
Our stockholders may be held liable for claims by third parties against us to the extent of distributions received by them upon redemption of their shares. |
• |
We may not hold an annual meeting of stockholders until after the consummation of our initial business combination. |
• |
We are a newly formed company with no operating history, and, accordingly, you have no basis on which to evaluate our ability to achieve our business objective. |
• |
If we are deemed to be an investment company under the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities may be restricted, which may make it difficult for us to complete our initial business combination. |
• |
We are an emerging growth company and a smaller reporting company within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements available to emerging growth companies, this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies. |
• |
Cyber incidents or attacks directed at us could result in information theft, data corruption, operational disruption and/or financial loss. |
• |
The risks set forth in the Risk Factors section of the Company’s registration statement and prospectus for the Company’s IPO filed with the SEC and “Item 1A. Risk Factors” of this Quarterly Report on Form 10-Q. |
ITEM 1. |
FINANCIAL STATEMENTS |
Assets |
||||
Current Assets |
||||
Cash |
$ | |||
Other assets |
||||
Total Current Assets |
||||
Deferred offering costs |
||||
Total Assets |
$ | |
||
Liabilities and Stockholders’ Equity |
||||
Current Liabilities: |
||||
Accrued expenses |
$ | |||
Accrued offering costs |
||||
Promissory note – related party |
||||
Total Liabilities |
$ | |||
Stockholders’ Equity: |
||||
Preferred stock, $ |
||||
Class A common stock, $ |
||||
Class B common stock, $ (1) |
||||
Additional paid-in capital |
||||
Accumulated deficit |
( |
) | ||
Total Stockholders’ Equity |
||||
Total Liabilities and Stockholders’ Equity |
$ | |||
(1) |
Includes up to shares of Class B |
For the Three Months Ended September 30, 2021 |
For the Period from March 24, 2021 (Inception) Through September 30, 2021 |
|||||||
Formation, general and administrative expenses |
$ | $ | ||||||
Net Loss |
$ | ( |
) | $ | ( |
) | ||
Basic and diluted weighted average shares outstanding (1) |
||||||||
Basic and diluted net loss per Class B common stock |
$ | ( |
) | $ | ( |
) | ||
(1) |
Excludes an aggregate of up to shares of Class B |
Preferred Stock |
Common Stock |
Additional Paid-in Capital |
Accumulated Deficit |
Total Stockholders’ Equity |
||||||||||||||||||||||||||||||||
Shares |
Amount |
Class A Shares |
Class A Amount |
Class B Shares |
Class B Amount |
|||||||||||||||||||||||||||||||
Balance at March 24, 2021 (inception) |
$ | |
$ | |
$ | |
$ | $ | $ | |||||||||||||||||||||||||||
Net loss |
— |
— |
— |
— |
— |
— |
— |
( |
) |
( |
) | |||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Balance at March 31, 2021 |
$ |
$ |
$ |
( |
) |
( |
) | |||||||||||||||||||||||||||||
Issuance of shares of Class B common stock to related parties (1) |
— |
— |
— |
— | — | |||||||||||||||||||||||||||||||
Net loss |
— |
— |
— |
— | — | — | — | ( |
) | ( |
) | |||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Balance at May 5, 2021 (audited) |
$ | $ | $ | ( |
) | |||||||||||||||||||||||||||||||
Net loss |
— |
— |
— |
— |
— |
— |
— |
( |
) |
( |
) | |||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Balance at June 30, 2021 (unaudited) |
$ |
$ |
$ |
( |
) | |||||||||||||||||||||||||||||||
Net Loss |
— |
— |
— |
— |
— |
— |
— |
( |
) |
( |
) | |||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Balance at September 30, 2021 (unaudited) |
$ | $ | $ | $ | |
$ | ( |
) | $ | |
||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
includes of Class B common stock subject |
Cash Flows from Operating Activities: |
||||
|
|
|||
Net loss |
$ | ( |
) | |
Changes in assets and liabilities: |
||||
Accrued expenses |
||||
Accrued offering costs |
||||
|
|
|||
Net cash used in operating activities |
( |
) | ||
|
|
|||
Cash Flows from Financing Activities: |
||||
Proceeds from the issuance of Class B common stock |
||||
|
|
|||
Net cash provided by financing activities |
||||
|
|
|||
Net change in cash |
||||
Cash-beginning of period |
||||
|
|
|||
Cash-end of period |
$ | |||
|
|
|||
Non-cash investing and financing activities: |
||||
Deferred offering costs included in accrued offering costs |
$ |
|||
Deferred offering costs included in promissory note – related party |
$ |
• | in whole and not in part; |
• | at a price of $ |
• | upon a minimum of “30-day redemption period”; and |
• | if, and only if, the last reported sale price of the Company’s Class A common stock for any |
• |
in whole and not in part; |
• | at $ Final Prospectus |
• | if, and only if, the Reference Value equals or exceeds $ |
• | if the Reference Value is less than $ |
• | may significantly dilute the equity interest of investors in the IPO, which dilution would increase if the anti-dilution provisions in our Class B common stock resulted in the issuance of our Class A common stock on a greater than one-to-one basis |
• | may subordinate the rights of holders of our Class A common stock if shares of preferred stock are issued with rights senior to those afforded our Class A common stock; |
• | could cause a change in control if a substantial number of shares of our Class A common stock are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors; |
• | may have the effect of delaying or preventing a change of control of us by diluting the share ownership or voting rights of a person seeking to obtain control of us; and |
• | may adversely affect prevailing market prices for our Class A common stock and/or warrants. |
• | default and foreclosure on our assets if our operating revenues after an initial Business Combination are insufficient to repay our debt obligations; |
• | acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant; |
• | our immediate payment of all principal and accrued interest, if any, if the debt is payable on demand; |
• | our inability to obtain necessary additional financing if the debt contains covenants restricting our ability to obtain such financing while the debt is outstanding; |
• | our inability to pay dividends on our common or preferred stock; |
• | using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our common stock if declared, our ability to pay expenses, make capital expenditures and acquisitions and fund other general corporate purposes; |
• | limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate; |
• | increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and |
• | limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements and execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt. |
* | Filed herewith. |
** | This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q and are not deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of the Exchange Act. |
(1) |
Previously filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on October 5, 2021 (File No. 001-40844). |
(2) |
Previously filed as an exhibit to the Company’s Registration Statement on Form S-1 (File No. 333-259324), filed |
SIGNATURE |
TITLE |
DATE | ||
/s/ Daniel Ciporin Daniel Ciporin |
Chairman, Chief Executive Officer (principal executive officer) | November 10, 2021 | ||
/s/ Jonathan Rosenzweig Jonathan Rosenzweig |
Chief Financial Officer, Secretary and Director (principal financial and accounting officer) | November 10, 2021 |